Clinical trials: MS, open to volunteers
Multiple Sclerosis
Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device
Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness.
- Trial name
- MSGH (NCT06410261)
- Testing
- Exercise rehabilitation program
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Illinois Chicago
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1.
- Trial name
- NCT07225361
- Testing
- Ublituximab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Northwestern University
Multiple Sclerosis
Assessment of Synaptic Density in MS
The investigators propose to use the novel SV2a-PET ligand, [F-18]SDM-8 to assess synaptic density in progressive multiple sclerosis (PMS) (including primary progressive multiple sclerosis (PPMS) and secondary progressive…
- Trial name
- NCT04634994
- Testing
- [F-18]SDM-8
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Traumatic Brain Injury, Cerebral Palsy
Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy
This prospective observational study collects real world data on participants receiving regenerative therapies administered internationally and delivered intranasally via the Kurve Therapeutics ViaNase device.
- Conditions
- Traumatic Brain Injury, Cerebral Palsy, Hypoxic Ischemic Encephalopathy, Neurologic Disorders
- Trial name
- MuSE-INSIGHT (NCT07521384)
- Where
- Mexico
- Volunteers
- 36 people
- Sponsor
- Healing Hope International
Acute Respiratory Disease
Estimation of P0.1 Using Ultrasound Indexes of Diaphragm Function
Occlusion pressure at 100 ms (P0.1) is a reliable and non-invasive index of inspiratory drive that can be measured easily on most ventilator. Unfortunately, P0.1 cannot be measured reliably in non-intubated patients.
- Trial name
- PoccUS (NCT07564258)
- Testing
- Spontaneous breathing trial
- Volunteers
- 40 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Rationale: Ocrelizumab is widely and effectively used to treat relapsing multiple sclerosis (RMS). Phase II studies and data from large patient cohorts indicate that rituximab, another anti-CD20 monoclonal antibody, is probably…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
- Trial name
- Noisy Rebels (NCT05834855)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Amsterdam UMC, location VUmc
Obesity, Obesity (Disorder)
Quality of Recovery and Patient Satisfaction After Metabolic Surgery at a Tertiary Hospital in Gauteng (QoRPS-MS)
PURPOSE OF THE STUDY?This study aims to assess patients' quality of recovery and satisfaction after metabolic surgery at a tertiary hospital in South Africa using two validated questionnaires.
- Conditions
- Obesity, Obesity (Disorder), Metabolic Disease
- Trial name
- QoRPS-MS (NCT07804290)
- Where
- South Africa
- Volunteers
- 84 people
- Sponsor
- Sefako Makgatho Health Sciences University
Primary Progressive Multiple Sclerosis, Primary Progressive MS
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.
- Conditions
- Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS)
- Trial name
- NCT07840326
- Testing
- SUN-627
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sundance Biosciences, Inc.
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory…
- Conditions
- Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progress Multiple Sclerosis (SPMS), Primary Progressive Multiple Sclerosis (PPMS)
- Trial name
- NCT07825389
- Testing
- C-CAR168
- Where
- 2 sites in United States
- Volunteers
- 119 people
- Sponsor
- AbelZeta Inc.
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
The goal of this observational study is to study the long-term effects of autologous hematopoietic stem cell transplantation (aHSCT) in people with highly active relapsing-remitting multiple sclerosis.
- Trial name
- MS-ACT (NCT06567197)
- Where
- 2 sites in Netherlands
- Volunteers
- 24 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Sclerosis (MS)
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
A randomized multiple baseline feasibility trial where participants will start taking metformin at one of 3 randomly determined points (3-months, 6-months or 9 months) during the 12-month trial.
- Trial name
- NCT04121468
- Testing
- Metformin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- The Hospital for Sick Children
Multiple Sclerosis (MS), Neurogenic Bladder Disorder
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients
The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.
- Conditions
- Multiple Sclerosis (MS), Neurogenic Bladder Disorder, Urinary Incontinence (UI), Urinary Urgency
- Trial name
- AROMA-MS (NCT07599189)
- Testing
- Essential Oil Blend (Lavender, Rosemary), Neutral Carrier Oil (Apricot Kernel Oil)
- Where
- 2 sites in Algeria
- Volunteers
- 60 people
- Sponsor
- University of Oran 1
Multiple Sclerosis, Balance
Technological Balance and Gait Rehabilitation in Patients With Multiple Sclerosis.
Multiple sclerosis (MS) is a chronic, inflammatory and neurodegenerative disease of the central nervous system that often results in motor and/or cognitive impairment.
- Conditions
- Multiple Sclerosis, Balance, Cognitive Impairment
- Trial name
- ROAR-MS (NCT05983809)
- Testing
- Technological rehabilitation
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Multiple Sclerosis
Acupressure in MS Patients
This study aims to evaluate the effects of acupressure therapy on patients with Multiple Sclerosis (MS). MS is a chronic autoimmune disease affecting the central nervous system, characterized by inflammation, demyelination, and…
- Trial name
- APEX-MS (NCT06755463)
- Testing
- Self-acupressure education
- Volunteers
- 82 people
- Sponsor
- Abant Izzet Baysal University
Multiple Sclerosis
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
- Trial name
- NCT04933552
- Testing
- Siponimod
- Where
- United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.
- Trial name
- FEMINISEP (NCT05754593)
- Testing
- Anti-Mullerian hormone (AMH) level, Antral follicle count (AFC), Clinical assessment
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Pancreas Cancer, Hepatocellular Carcinoma
Analysis of Breath Volatile Organic Compounds Using Mass Spectrometry
The purpose of this clinical trial is to evaluate whether volatile organic compound (VOC) signatures detected in the breath of patients with cancer can serve as a potential screening tool for the early detection of cancer.
- Conditions
- Pancreas Cancer, Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer
- Trial name
- NCT07732686
- Testing
- Proton Transfer Reaction Mass Spectrometry Analysis
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Relapsing-Remitting Multiple Sclerosis
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
The main purpose of the study is to assess patient-reported satisfaction with subcutaneous (s.c.) ocrelizumab administration in participants with relapsing-remitting multiple sclerosis (RRMS) who are treatment-naive, switching…
- Trial name
- SONATA-MS (NCT07827586)
- Testing
- Ocrelizumab
- Where
- 2 sites in Czechia, Slovenia
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis.
- Trial name
- TAG-MS (NCT07497399)
- Testing
- NLY01
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Johns Hopkins University